Literature DB >> 3665184

Characterization of anti-liver kidney microsomal antibody in childhood autoimmune chronic active hepatitis: evidence for IgG1 subclass restriction, polyclonality and non cross-reactivity with hepatocyte surface antigens.

M Peakman1, A Lobo-Yeo, G Mieli-Vergani, E T Davies, A P Mowat, D Vergani.   

Abstract

An indirect immunofluorescence technique was used to investigate the immunoglobulin class, IgG subclass, light chain type and complement fixing ability of anti-liver kidney microsomal antibody (anti-LKM) in the sera of six children and five adults with autoimmune chronic active hepatitis (aCAH). Anti-LKM titres ranged from 1/80 to 1/20,480. In the children, the antibody belonged to the IgG1 subclass alone (titre 1/80-1/20,480) and was able to fix complement (titre 1/40-1/5120). In the adult group, antibody belonged to the IgG1 subclass in three cases (titre 1/40-1/640) whilst two belonged to both IgG1 (titre 1/640) and IgG4 (titre 1/40, 1/640). Such subclass restriction is similar to that found in other autoimmune disorders and may be genetically determined. Investigation of the light chain constituent of anti-LKM revealed that the kappa to lambda ratio was consistent with a polyclonal antibody response. To investigate the nature of the antigen to which anti-LKM is directed, the ability of these sera to bind to the surface membrane of isolated human hepatoma cells (Alexander cells) was investigated. Four of the eleven sera showed significant binding activity. Prior incubation of these four sera with Alexander cells abolished their membrane binding activity, but did not alter the anti-LKM titre. These results suggest that anti-LKM binds to cytoplasmic constituents alone and does not cross-react with surface antigens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665184      PMCID: PMC1542376     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Characterization of the microsomal antigen related to a subclass of active chronic hepatitis.

Authors:  M Rizzetto; F B Bianchi; D Doniach
Journal:  Immunology       Date:  1974-03       Impact factor: 7.397

2.  Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes.

Authors:  T Ishizaka; K Ishizaka; S Salmon; H Fudenberg
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

Review 3.  Human immunoglobulins: classes, subclasses, genetic variants, and idiotypes.

Authors:  J B Natvig; H G Kunkel
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

4.  Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study.

Authors:  R Jefferis; C B Reimer; F Skvaril; G de Lange; N R Ling; J Lowe; M R Walker; D J Phillips; C H Aloisio; T W Wells
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

5.  Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing gamma, epsilon and alpha genes.

Authors:  J G Flanagan; T H Rabbitts
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

6.  Interaction of HLA and Gm in autoimmune chronic active hepatitis.

Authors:  S Whittingham; J D Mathews; M S Schanfield; B D Tait; I R Mackay
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

7.  HLA associations with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies.

Authors:  I R Mackay; B D Tait
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

8.  Hepatic disorders associated with liver-kidney microsomal antibodies.

Authors:  M G Smith; R Williams; G Walker; M Rizzetto; D Doniach
Journal:  Br Med J       Date:  1974-04-13

9.  Functional properties of lymphocyte subpopulations in hepatitis B virus infection. II. Cytotoxic effector cell killing of targets that naturally express hepatitis B surface antigen and liver-specific lipoprotein.

Authors:  F V Chisari; M S Bieber; C A Josepho; C Xavier; D S Anderson
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

10.  The interaction between human monocytes and red cells. Specificity for IgG subclasses and IgG fragments.

Authors:  N Abramson; E W Gelfand; J H Jandl; F S Rosen
Journal:  J Exp Med       Date:  1970-12-01       Impact factor: 14.307

View more
  6 in total

1.  Antireticulin antibody in systemic sclerosis.

Authors:  T Mahmud; M Peakman; G Senaldi; A McWhirter; C M Black; D Vergani
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

2.  Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.

Authors:  R Klein; U M Zanger; T Berg; U Hopf; P A Berg
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

3.  A new antigen recognized by anti-liver-kidney-microsome antibody (LKMA).

Authors:  P Codońer-Franch; K Paradis; M Gueguen; O Bernard; A A Costesec; F Alvarez
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

4.  Cytochrome P450IID6 recognized by LKM1 antibody is not exposed on the surface of hepatocytes.

Authors:  A M Yamamoto; C Mura; C De Lemos-Chiarandini; R Krishnamoorthy; F Alvarez
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

5.  Lymphocyte subset abnormalities, autoantibodies and their relationship with HLA DR types in children with type 1 (insulin-dependent) diabetes and their first degree relatives.

Authors:  M Peakman; T Warnock; A Vats; G L McNab; J Underhill; P T Donaldson; D Vergani
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

6.  Characterization of islet cell antibody in insulin dependent diabetes: evidence for IgG1 subclass restriction and polyclonality.

Authors:  A Millward; M J Hussain; M Peakman; D A Pyke; R D Leslie; D Vergani
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.